Download PDF
Am J Perinatol
DOI: 10.1055/a-1979-8501
Original Article

Urine Desmosine as a Novel Biomarker for Bronchopulmonary Dysplasia and Postprematurity Respiratory Disease in Extremely Preterm or Low Birth Weight Infants

Katsuya Hirata 
1   Department of Neonatal Medicine, Osaka Women's and Children's Hospital, Osaka, Japan
,
Masanori Nishikawa
2   Department of Radiology, Osaka Women's and Children's Hospital, Osaka, Japan
,
Masatoshi Nozaki
1   Department of Neonatal Medicine, Osaka Women's and Children's Hospital, Osaka, Japan
,
Hiroyuki Kitajima
1   Department of Neonatal Medicine, Osaka Women's and Children's Hospital, Osaka, Japan
,
Itaru Yanagihara
3   Department of Developmental Medicine, Research Institute, Osaka Women's and Children's Hospital, Osaka, Japan
,
Kazuko Wada
1   Department of Neonatal Medicine, Osaka Women's and Children's Hospital, Osaka, Japan
,
Masanori Fujimura
1   Department of Neonatal Medicine, Osaka Women's and Children's Hospital, Osaka, Japan
› Author Affiliations Funding This work was supported by the Sukoyaka Grant for Maternal and Child Health (K. H.) and research grants from the JSPS KAKENHI (grant no.: JP20H03564 to I. Y.).
› Further Information
    Permissions and Reprints

Abstract

Objective This study aimed to evaluate whether elevated urine desmosine levels at 3 weeks of age were associated with severe radiological findings, bronchopulmonary dysplasia (BPD), and post-prematurity respiratory disease (PRD) in extremely preterm (EP) or extremely low birth weight (ELBW) infants.

Study Design This study recruited 37 EP (22–27 completed weeks) or ELBW (<1,000 g) infants. Urine was collected between 21 and 28 postnatal days, and desmosine was measured using an enzyme-linked immunosorbent assay kit; the urine creatinine level was also measured. Bubbly/cystic lungs were characterized by emphysematous chest X-rays on postnatal day 28. Furthermore, provision of supplemental oxygen or positive-pressure respiratory support at 40 weeks' postmenstrual age defined BPD, and increased medical utilization at 18 months of corrected age defined PRD. The desmosine/creatinine threshold was determined by receiver operating characteristic analysis. The adjusted risk and 95% confidence interval (CI) for elevated urine desmosine/creatinine levels were estimated by logistic regression analysis.

Results Elevated urine desmosine/creatinine levels higher than the threshold were significantly associated with bubbly/cystic lungs (8/13 [61.5%] vs. 2/24 [8.3%], p = 0.001), BPD (10/13 [76.9%] vs. 8/24 [33.3%], p = 0.02), and PRD (6/13 [46.2%] vs. 2/24 [8.3%], p = 0.01). After adjusting for gestational age, birth weight, and sex, the urine desmosine/creatinine levels were significantly higher in those who were highly at risk of bubbly/cystic lungs (odds ratio [OR], 13.2; 95% CI, 1.67–105) and PRD (OR, 13.8; 95% CI, 1.31–144).

Conclusion Elevated urine desmosine/creatinine levels on the third postnatal week were associated with bubbly/cystic lungs on day 28 and PRD at 18 months of corrected age in EP or ELBW infants.

Key Points

  • Urine desmosine was prospectively measured in 3-week-old EP/ELBW infants.

  • Elevated urine desmosine levels were associated with emphysematous radiological findings on day 28, PRD at 18 months of corrected age.

  • Urine desmosine may be a promising biomarker indicating lung damage in EP/ELBW infants.

Keywords

biomarker - bronchopulmonary dysplasia - desmosine - extremely low birth - extremely preterm infant

Ethical Statement

This study protocol was reviewed and approved by the Osaka Women's and Children's Hospital Institutional Review Board (approval number: 1175). Written informed consent was obtained from the parents. This study was conducted following the Declaration of Helsinki.


Authors' Contributions

K. H. and M. F. conceptualized and designed the research. K. H., M. No., and K. W. collected and analyzed the data. K. H. wrote the manuscript. M. Ni., H. K., I. Y., and M. F. assisted with study design and reviewed the manuscript. M. F. reviewed and revised the manuscript. All authors read and approved the final manuscript.


Data Availability Statement

Additional anonymized data are available from the corresponding author upon reasonable requests.


Supplementary Material



Publication History

Received: 04 August 2022

Accepted: 08 November 2022

Accepted Manuscript online:
16 November 2022

Article published online:
21 December 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Thébaud B, Goss KN, Laughon M. et al. Bronchopulmonary dysplasia. Nat Rev Dis Primers 2019; 5 (01) 78
    CrossrefPubMedGoogle Scholar
  • 2 Higgins RD, Jobe AH, Koso-Thomas M. et al. Bronchopulmonary dysplasia: executive summary of a workshop. J Pediatr 2018; 197: 300-308
    CrossrefPubMedGoogle Scholar
  • 3 Bonadies L, Zaramella P, Porzionato A, Perilongo G, Muraca M, Baraldi E. Present and future of bronchopulmonary dysplasia. J Clin Med 2020; 9 (05) 9
    CrossrefPubMedGoogle Scholar
  • 4 Cheong JLY, Doyle LW. An update on pulmonary and neurodevelopmental outcomes of bronchopulmonary dysplasia. Semin Perinatol 2018; 42 (07) 478-484
    CrossrefPubMedGoogle Scholar
  • 5 Doyle LW, Carse E, Adams AM, Ranganathan S, Opie G, Cheong JLY. Victorian Infant Collaborative Study Group. Ventilation in extremely preterm infants and respiratory function at 8 years. N Engl J Med 2017; 377 (04) 329-337
    CrossrefPubMedGoogle Scholar
  • 6 Jensen EA, Dysart K, Gantz MG. et al. The diagnosis of bronchopulmonary dysplasia in very preterm infants. An evidence-based approach. Am J Respir Crit Care Med 2019; 200 (06) 751-759
    CrossrefPubMedGoogle Scholar
  • 7 Isayama T, Lee SK, Yang J. et al; Canadian Neonatal Network and Canadian Neonatal Follow-Up Network Investigators. Revisiting the definition of bronchopulmonary dysplasia: Effect of changing panoply of respiratory support for preterm neonates. JAMA Pediatr 2017; 171 (03) 271-279
    CrossrefPubMedGoogle Scholar
  • 8 Charafeddine L, D'Angio CT, Phelps DL. Atypical chronic lung disease patterns in neonates. Pediatrics 1999; 103 (4, pt. 1): 759-765
    CrossrefPubMedGoogle Scholar
  • 9 Laughon M, Allred EN, Bose C. et al; ELGAN Study Investigators. Patterns of respiratory disease during the first 2 postnatal weeks in extremely premature infants. Pediatrics 2009; 123 (04) 1124-1131
    CrossrefPubMedGoogle Scholar
  • 10 Wai KC, Kohn MA, Ballard RA. et al; Trial of Late Surfactant (TOLSURF) Study Group. Early cumulative supplemental oxygen predicts bronchopulmonary dysplasia in high risk extremely low gestational age newborns. J Pediatr 2016; 177: 97-102.e2
    CrossrefPubMedGoogle Scholar
  • 11 Dylag AM, Kopin HG, O'Reilly MA. et al. Early neonatal oxygen exposure predicts pulmonary morbidity and functional deficits at 1 year. J Pediatr 2020; 223: 20-28.e2
    CrossrefPubMedGoogle Scholar
  • 12 Greenberg RG, McDonald SA, Laughon MM. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Online clinical tool to estimate risk of bronchopulmonary dysplasia in extremely preterm infants. Arch Dis Child Fetal Neonatal Ed 2022; ( e-pub ahead of print ). DOI: 10.1136/archdischild-2021-323573.
    CrossrefPubMedGoogle Scholar
  • 13 Hirata K, Nishihara M, Shiraishi J. et al. Perinatal factors associated with long-term respiratory sequelae in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2015; 100 (04) F314-F319
    CrossrefPubMedGoogle Scholar
  • 14 Arai H, Ito M, Ito T, Ota S, Takahashi T. Neonatal Research Network of Japan. Bubbly and cystic appearance on chest radiograph of extremely preterm infants with bronchopulmonary dysplasia is associated with wheezing disorder. Acta Paediatr 2020; 109 (04) 711-719
    CrossrefPubMedGoogle Scholar
  • 15 van Mastrigt E, Logie K, Ciet P. et al. Lung CT imaging in patients with bronchopulmonary dysplasia: a systematic review. Pediatr Pulmonol 2016; 51 (09) 975-986
    CrossrefPubMedGoogle Scholar
  • 16 Higano NS, Spielberg DR, Fleck RJ. et al. Neonatal pulmonary magnetic resonance imaging of bronchopulmonary dysplasia predicts short-term clinical outcomes. Am J Respir Crit Care Med 2018; 198 (10) 1302-1311
    CrossrefPubMedGoogle Scholar
  • 17 Vanhaverbeke K, Van Eyck A, Van Hoorenbeeck K. et al. Lung imaging in bronchopulmonary dysplasia: a systematic review. Respir Med 2020; 171: 106101
    CrossrefPubMedGoogle Scholar
  • 18 Laguna TA, Wagner BD, Starcher B. et al. Urinary desmosine: a biomarker of structural lung injury during CF pulmonary exacerbation. Pediatr Pulmonol 2012; 47 (09) 856-863
    CrossrefPubMedGoogle Scholar
  • 19 Luisetti M, Ma S, Iadarola P. et al. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J 2008; 32 (05) 1146-1157
    CrossrefPubMedGoogle Scholar
  • 20 Kim C, Ko Y, Kim SH. et al. Urinary desmosine is associated with emphysema severity and frequent exacerbation in patients with COPD. Respirology 2018; 23 (02) 176-181
    CrossrefPubMedGoogle Scholar
  • 21 Huang JT, Chaudhuri R, Albarbarawi O. et al. Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. Thorax 2012; 67 (06) 502-508
    CrossrefPubMedGoogle Scholar
  • 22 Oyama Y, Enomoto N, Suzuki Y. et al. Evaluation of urinary desmosines as a noninvasive diagnostic biomarker in patients with idiopathic pleuroparenchymal fibroelastosis (PPFE). Respir Med 2017; 123: 63-70
    CrossrefPubMedGoogle Scholar
  • 23 Fujimura M, Kitajima H, Nakayama M. Increased leukocyte elastase of the tracheal aspirate at birth and neonatal pulmonary emphysema. Pediatrics 1993; 92 (04) 564-569
    CrossrefPubMedGoogle Scholar
  • 24 Namba F, Fujimura M, Tamura M. Bubbly and cystic appearance in chronic lung disease: is this diagnosed as Wilson-Mikity syndrome?. Pediatr Int 2016; 58 (04) 251-253
    CrossrefPubMedGoogle Scholar
  • 25 Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol 2003; 23 (06) 451-456
    CrossrefPubMedGoogle Scholar
  • 26 Keller RL, Feng R, DeMauro SB. et al; Prematurity and Respiratory Outcomes Program. Bronchopulmonary dysplasia and perinatal characteristics predict 1-year respiratory outcomes in newborns born at extremely low gestational age: a prospective cohort study. J Pediatr 2017; 187: 89-97.e3
    CrossrefPubMedGoogle Scholar
  • 27 Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48 (03) 452-458
    CrossrefPubMedGoogle Scholar
  • 28 Hirata K, Nishihara M, Kimura T. et al. Longitudinal impairment of lung function in school-age children with extremely low birth weights. Pediatr Pulmonol 2017; 52 (06) 779-786
    CrossrefPubMedGoogle Scholar
  • 29 Ito M, Tomotaki S, Isayama T, Hara H, Hirata K, Arai H. The status of chronic lung disease diagnosis in Japan: secondary publication. Pediatr Int 2022; 64 (01) e15184
    CrossrefPubMedGoogle Scholar
  • 30 Bruce MC, Wedig KE, Jentoft N. et al. Altered urinary excretion of elastin cross-links in premature infants who develop bronchopulmonary dysplasia. Am Rev Respir Dis 1985; 131 (04) 568-572
    CrossrefPubMedGoogle Scholar
  • 31 Bruce MC, Schuyler M, Martin RJ, Starcher BC, Tomashefski Jr JF, Wedig KE. Risk factors for the degradation of lung elastic fibers in the ventilated neonate. Implications for impaired lung development in bronchopulmonary dysplasia. Am Rev Respir Dis 1992; 146 (01) 204-212
    CrossrefPubMedGoogle Scholar
  • 32 Kitajima H, Fujimura M, Takeuchi M. et al. Intrauterine Ureaplasma is associated with small airway obstruction in extremely preterm infants. Pediatr Pulmonol 2022; 57 (11) 2763-2773
    CrossrefPubMedGoogle Scholar